Dr. Ryan on Bone-Targeting Agents for Patients With Prostate Cancer

Charles J. Ryan, MD
Published: Wednesday, Nov 01, 2017



Charles J. Ryan, MD, professor of medicine and urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses bone-targeting agents for patients with prostate cancer.

Ryan aims to initiate bisphosphates or RANK-ligand targeted therapies before a patient's risk for boney complications gets too serious and there are adverse prognostic factors.

With patients who have progressive disease, Ryan might initiate the bone-targeted therapy at the same time as the antitumor therapy, such as abiraterone acetate (Zytiga), enzalutamide (Xtandi), and denosumab (Prolia).

It is still unclear when these agents should be started, when the greatest benefit is leveraged, and whether the treatment should be shortened or discontinued, says Ryan. More long-term studies need to be conducted, explains Ryan.


Charles J. Ryan, MD, professor of medicine and urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses bone-targeting agents for patients with prostate cancer.

Ryan aims to initiate bisphosphates or RANK-ligand targeted therapies before a patient's risk for boney complications gets too serious and there are adverse prognostic factors.

With patients who have progressive disease, Ryan might initiate the bone-targeted therapy at the same time as the antitumor therapy, such as abiraterone acetate (Zytiga), enzalutamide (Xtandi), and denosumab (Prolia).

It is still unclear when these agents should be started, when the greatest benefit is leveraged, and whether the treatment should be shortened or discontinued, says Ryan. More long-term studies need to be conducted, explains Ryan.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x